Study to Determine the Safety and Efficacy of Teneligliptin (20 Mg) in Naive Type 2 Diabetes Mellitus
Journal Title: International Journal Of Medical Science And Clinical Research Studies - Year 2023, Vol 3, Issue 3
Abstract
Background: Teneligliptin is a novel, highly selective DPP-4 inhibitor with long half-life, approved in Japan (2012) and in Korea (2014) to treat patients of type 2 DM. It is characterized by a considerably rigid structure formed by five consecutive rings.Teneligliptin, 20mg/day as monotherapy and combination therapy in type 2 DM was shown to be effective in reducing HbA1c and fasting plasma glucose levels without any significant adverse events. Present study was conducted to determine the safety and efficacy of Teneligliptin (20 mg) in naive type 2 diabetes mellitus. Materials and methods:The present study was a hospital based prospective study undertaken to study the safety and efficacy of teneligliptin (20 mg) in naïve type 2 diabetes mellitus. Newly diagnosed type 2 diabetes mellitus patients within age group 18-70 years were studied. All patients were assessed for Blood sugar levels (Fasting and Postprandial HbA1C, Serum urea, Serum Creatinine, Serum uric acid, Lipid profile and ECG. Results: The mean age of total patients was 52.86 ±9.24 years. The mean HbA1c among patients with DM was 7.76 ±1.61. The mean serum urea was 29.12±6.58mg/dl while Serum creatinine was 1.08±0.18 mg/dl. The mean fasting Blood sugar of the patients before treatment was 123.55 ±10.72 and 103.12 ±8.63 mg/dl after treatment with statistical significant difference (p<0.05). The mean blood urea of the patients before treatment was 29.12 ±6.58 and 20.86 ±5.04 mg/dl after treatment with no statistical significant difference. (p >0.05) The mean QT interval of the patients before treatment was 0.37±0.03 and 0.38±0.03 seconds after treatment with statistical non-significant difference (p <0.05). Conclusion: The present study concludes that, Teneligliptin, a novel DPP-4I, when prescribed as a monotherapy antidiabetic agent in a dose of 20 mg daily, significantly improved glycemic parameters. The results of this study suggest that teneligliptin can be considered to be an effective antidiabetic agent in the management of Indian patients with type naive 2 Diabetes Mellitus.
Authors and Affiliations
Subhash Chandra , Pulkit Chaudhary , Vagish Baranwal
Keywords
Related Articles
- EP ID EP739963
- DOI 10.47191/ijmscrs/v3-i3-40
- Views 3
- Downloads 0
How to Avoid Nipple Necrosis in Lifting and Reduction Mammaplasties
Partial or complete nipple areolar complex (NAC) necrosis following breast reduction mammaplasties is an overwhelming complication for both the plastic surgeon and the patient. Its reported incidence vary from 2% for...
A Systematic Review of Procyanidins: Updates on Current Bioactivities and Potential Benefits in Wound Healing
Introduction:Procyanidins are a class of flavonoids found in many fruits and plants and have been used as traditional medicine or other homemade remedies, particularly for wound healing. This study systematically reviews...
A case review of De Garengeot's hernia
De Garengeot'shernia was described in 1731, referring to it as the presence of the appendix in a femoral hernia. It occurs in between 0.5% and 5% of cases. It is believed to perform simple hernia surgery and avoid using...
Differentiating Between Population and Target Population in Research Studies
Research methods of any postgraduate study entail a description of a population of interest from which the target population and the sample are derived. A clear distinction between these concepts is essential for researc...
Efficacy, Safety of Baricitinib plus Remdesivir versus Standard Therapy (Remdesivir) in Patients with Severe COVID-19 Infection in Third Wave of Epidemics in Myanmar: Case Control Study
threat to health around the world as it causes significant morbidity and mortality. SARS-CoV-2 infection induces severe inflammation in lungs and multi-organs; therefore, the Janus kinase (JAK) inhibitor known as baricit...